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Purpose: To evaluate and compare real world cost-effectiveness of inhaled corticosteroids 
(ICS) administered by metered dose inhaler (MDI), breath-actuated MDI (BAI), or dry powder 
inhaler (DPI) in asthma.
Patients and methods: This retrospective database study analyzed the direct health care 
costs and proportion of patients (aged 5–60 years) achieving asthma control over 1 year in two 
population groups: those starting ICS (initiation population) and those receiving a first increase 
in ICS dose (step-up population). Asthma control was defined as no unplanned asthma visits, 
oral corticosteroids, or antibiotics for lower respiratory infection; outcomes were adjusted for 
confounding variables. Cost-effectiveness of BAI and DPI were compared with MDI.
Results: For the initiation population (n = 56,347), average annual health care costs per person 
(adjusted results), as compared with MDIs, were £9 higher (95% CI: −1.65 to 19.71) for BAIs 
and £32 higher (95% CI: 19.51 to 43.66) for DPIs. The probability of BAIs being the dominant 
strategy (more effective and less costly than MDIs) was 5% and of BAIs being more effective 
and more costly than MDIs was 94%. DPIs were consistently more effective and more costly 
than MDIs, with an incremental cost-effectiveness ratio of £1711 (95% CI: 760 to 3,576) per 
  additional   controlled patient per year. For the step-up population (n = 9169), mean total health 
care costs per person, (adjusted) as compared with MDIs, were £1 higher (95% CI: −27.28 to 
31.55) for BAIs and £73 higher (95% CI: 44.48 to 103.29) for DPIs. The probability of BAIs 
being dominant was 48% and of BAIs being more effective but more costly than MDIs was 52%; 
the probability of DPIs being more effective but more costly than MDIs was 96%.
Conclusion: The real world effectiveness of ICS inhalers may vary, and inhaler device   selection 
for patients with asthma should take into consideration not only initial device cost but also the 
subsequent health care resource costs.
Keywords: asthma control, breath-actuated inhaler, dry powder inhaler, metered dose inhaler, 
incremental cost-effectiveness ratio
Asthma affects over 300 million people worldwide and has a substantial economic 
impact.1 Estimated costs of asthma to the National Health Service in the United 
Kingdom (UK NHS) are £1 billion per year,2,3 with total associated costs in the UK 
of over £2.3 billion per year.4 Much of the economic burden of asthma results from 
poorly controlled disease and asthma exacerbations, which contribute to increased 
direct medical expenditures related to emergency care as well as indirect costs of lost 
work time and lost productivity.5–7
Asthma is often poorly controlled. In one western European asthma survey, only 
5.3% of patients met all criteria for asthma control,8 and other international surveys 
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  similarly indicate that many patients do not achieve control 
of their asthma.9,10 Much work thus remains to improve 
asthma control, as it has been shown that those with 
poor asthma control are more likely to suffer exacerbations 
of asthma requiring unscheduled care.11
Inhalation therapy is the cornerstone of asthma   treatment, 
used for delivery of ‘reliever’ bronchodilators such as 
  salbutamol, as well as anti-inflammatory   corticosteroid 
‘  controller’ therapies. Currently available inhaler devices 
include pressurized metered dose inhalers (MDIs), 
  breath-actuated MDIs (BAIs), and dry powder inhalers 
(DPIs). Both BAIs and DPIs are actuated by the patient’s 
inhalation maneuver, while MDIs require coordination 
by the patient of actuation and inhalation. The clinical 
  effectiveness of inhalation therapy derives from delivery 
of the drug to   target sites in the lungs, and evidence is 
mounting that   incorrect use of inhaler devices is a common 
problem contributing to incomplete asthma control for many 
patients.12,13 Indeed, decreased asthma control has been linked 
to the   number of mistakes made when using MDIs for the 
delivery of inhaled corticosteroids (ICS).14 Moreover, there is 
evidence that patients’ abilities regarding use of the different 
inhaler device types are variable.13,15,16
Recent reviews of randomized controlled trials (RCTs), 
while recognizing the importance of inhaler technique, have 
concluded that inhaler devices do not differ   significantly 
in efficacy17–19 and that the cheapest inhaler device should 
be used.18 However, these results, because they are based 
on RCTs, should be applied with caution to the broader 
  population of patients with asthma in primary care   settings, 
over 90% of whom do not qualify for inclusion in RCTs 
because of comorbidity, smoking habits, or the lack of 
‘s  ufficient’ lung function impairment.20,21 Importantly, 
patients enrolled in RCTs typically receive extensive device 
training and must demonstrate and maintain proper inhaler 
technique, which can seldom be accomplished in a real 
world setting.
Observational studies can provide important information 
to supplement that from RCTs.22,23 While RCTs are designed 
to eliminate confounding factors and maximize internal 
validity, the results of well-conducted observational studies 
of broader populations are more applicable (ie,   generalizable) 
to patients seen in general practice. For this reason, and 
because of the opportunity for long term follow up that is 
so important in studying a chronic disease, database studies 
have been recommended for health economic evaluations in 
asthma.24,25 Indeed, the findings of one observational study, 
using a large primary care database, suggest that inhaler 
device does impact asthma outcomes as well as health care 
resource use.26
Our objective in this retrospective observational study 
was to evaluate the ‘real world’ cost-effectiveness of three 
different inhaler devices – BAI or DPI as compared with 
the more commonly prescribed MDI – for delivering ICS 
in asthma, as captured in a large primary care database. 
Outcomes and costs, calculated from the perspective of 
the UK NHS, were studied for two populations of primary 
care patients with asthma: those initiating ICS therapy and 
those prescribed an increased dose of ICS.
Methods
Data for these analyses were extracted from patient records 
in the UK General Practice Research Database (GPRD) 
from January 1997 to the end of June 2007, a period when 
all inhaler types under study were available. The GPRD 
  contains   de-identified medical records from approximately 
500   primary care practices throughout the UK, including 
3.6 million active records and 13 million records overall.27 
Validated and used frequently for epidemiologic research,28–30 
the GPRD applies a standard set of criteria relating to 
  registration details to define which data are acceptable for 
research. Specifically, data recorded after the practice ‘up-to-
standard date’ are   considered research quality, prospectively 
recorded data.
To be included in the current analyses, patients must have 
been registered at the same practice and had up-to-standard 
  follow up data for at least 12 months before and 12 months 
after the index prescription date of the start of ICS therapy 
(initiation population) or a first increase in ICS dose (step-up 
population). Patients eligible for the step-up population had 
to have at least one recorded prescription for ICS during the 
year before the index date (baseline year). Eligible patients in 
both the initiation and step-up populations were aged between 
5 and 60 years on the index date and had persistent asthma, 
as evidenced by a recorded diagnosis of asthma or two or 
more prescriptions for ICS for asthma at more than one time 
point during the year after the index date (outcome year). 
Patients were excluded if their record contained a diagnostic 
code for any chronic respiratory condition other than asthma, 
including chronic obstructive pulmonary disease (COPD), 
or if they were prescribed more than one ICS or ICS device 
on the index date.
The GPRD Independent Scientific Advisory   Committee 
approved the use of GPRD data for this study as part 
of a broader evaluation of the effectiveness of differing 
  interventions in obstructive lung disease.ClinicoEconomics and Outcomes Research 2010:2
Table 1 Unit costs for health care resources applied in the study 
(2007 pounds sterling, £)
Health care resource type Unit cost, £
Primary care consultation 34.00
Respiratory outpatient consultation 127.00
Respiratory inpatient admissions 761.50
Respiratory emergency room visit 144.61
nonrespiratory inpatient admission 1,576.57
nonrespiratory outpatient attendances 167.95
nonrespiratory emergency room visit 89.40
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Outcomes
All outcomes and approaches to analysis were predefined 
before the analyses were performed according to Standard 
Operating Procedures published by the study group.31
Data from the baseline year were used to establish patient 
eligibility and identify likely confounding factors. The 
  primary end point was the cost to achieve an additional   person 
meeting the asthma control measure during the outcome 
year. The ‘asthma control measure’ was a composite proxy 
measure defined as: 1) no recorded hospital attendance for 
asthma (neither admission nor attendance at the emergency 
department or outpatient department, or use of afterhours 
services); 2) no prescription for oral corticosteroids; and 3) no 
consultation, hospital admission, or emergency department 
attendance for lower respiratory tract infection requiring 
antibiotics. A second composite, the ‘revised asthma control 
measure’, which approximates to the well controlled asthma 
status in the GINA guidelines,32 incorporated an additional 
parameter, namely: 4) average daily prescribed dose of 
salbutamol of #200 µg (or terbutaline #500 µg).
Health care resource use, including asthma therapy and 
respiratory-related consultations and hospitalizations, was 
drawn from the GPRD for the baseline year and the outcome 
period of 1 year after the index prescription date. Quantities 
were multiplied by unit costs derived from UK national data 
sources to calculate total costs from the UK NHS   perspective 
in 2007 pounds sterling (£). Hospital-related costs were 
derived from the 2006–2007 NHS Reference Costs,33 and 
general practice costs were drawn from the Personal Social 
Services Research Unit at the University of Kent.34 Unit 
costs applied for respiratory- and nonrespiratory-related 
  consultations and visits are summarized in Table 1.
Unit costs for medications were sourced from the 
GPRD and, if not available there, from the Prescription 
Cost   Analysis for England for 2007.35 Product names used 
in the GPRD were cross-referenced to the British National 
  Formulary (BNF) drug names as closely as possible.36 
The cheapest price was taken if there were any ambiguity. 
For preparations that were not available in 2007, unit costs 
were used from either 2002, 2000, or 1998 and multiplied 
by inflation factors based on the retail price index of 1.17, 
1.21, and 1.27, respectively. The numbers of tablets and 
inhalers were used when possible, rather than assuming a 
standard pack size.
statistical analyses
Patients prescribed ICS using BAIs or DPIs were defined 
as the cohorts of interest and were compared with patients 
  prescribed MDIs as the reference cohort. Results were 
  examined separately for the populations new to ICS and 
those receiving their first increased dose of ICS.
The probabilities of achieving the two asthma control 
  measures were calculated using a binary logistic   regression 
model (1,000 replications) with asthma   control as the   dependent 
variable and cohort, together with potential   confounding 
factors (year of index date, age, sex,   socioeconomic status, 
comorbidity, and treatment with medication that could affect 
respiratory outcomes), as explanatory variables. Confounding 
factors included   variables that were significantly different 
(P # 0.05) among cohorts at baseline or that were predictive 
of asthma control based on   univariate analysis (P # 0.05). 
  Adjustments were made for the   following   confounding vari-
ables as noted: age,   categorized as 5–12, 13–20, 21–30, 31–40, 
41–50, 51–60 years; sex;   socioeconomic status (log scale); 
comorbidities including   gastroesophageal reflux   disease 
  diagnosis, cardiac disease diagnosis,   rhinitis   diagnosis, 
Charlson   comorbidity index (CCI) score; and beta   blockers, 
nonsteroidal anti-inflammatory agents, and   paracetamol. 
  Respiratory-related outcomes included as confounding   factors 
were oral corticosteroid courses,   categorized as 0, 1, 2, or $3; 
antibiotics; hospital admissions for asthma and   respiratory 
disease; outpatient attendance; asthma   prescriptions; asthma 
consultations; short-acting β2 agonist (SABA) dose, catego-
rized as 0, .0–100 µg, 101–200 µg, 201–400 µg, 401–800 µg, 
.800 µg; ICS dose at index prescription date, categorized as 
0–200 µg, 201–400 µg, 401–800 µg, .800 µg; and year of 
index   prescription. The dose of ICS was normalized to the 
  beclomethasone   dipropionate (BDP) equivalent dose, using 
ratios of 1:1:2:2:2 for BDP, budesonide, fluticasone propi-
onate, BDP in solution (QVAR®, Teva UK), and mometasone, 
respectively.
Socioeconomic status was the score assigned by the GPRD 
to each practice using the Index of Multiple   Deprivation 
(IMD) as a proxy measure. The CCI score,37 a weighted index 
accounting for number and severity of   comorbidities, was ClinicoEconomics and Outcomes Research 2010:2
Table  2  Demographic  and  baseline  characteristics  of  patients  receiving  a  first  prescription  or  an  increased  dose  of  inhaled 
corticosteroid, by inhaler device type
Patients starting ICS Patients receiving an increased dose of ICS
MDI 
(n = 39,746)
BAI 
(n = 9809)
DPI 
(n = 6792)
MDI 
(n = 6245)
BAI 
(n = 1388)
DPI 
(n = 1536)
Male sex 17,294 (43.5)b 4,062 (41.4) 3,013 (44.4) 2,735 (43.8)b 571 (41.1) 735 (47.9)
Age at index date (y) 28 (12–42)b 30 (13–45) 22 (11–42) 27 (10–45) 21 (12–44) 20 (11–42)
Baseline asthma 
controlc
30,129 (75.8)a 7,328 (74.7) 5,205 (76.6) 3,727 (59.7)b 927 (66.8) 977 (63.6)
Total asthma/resp 
costs
34.00b 
(0–68.00)
35.47 
(1.47–70.32)
34.00 
(0–69.59)
103.13b 
(54.82–180.87)
101.69 
(58.63–173.68)
127.42 
(77.38–222.06)
Total asthma/resp 
costs excl iCs
– – – 77.28b 
(38.98–148.47)
78.46 
(40.30–143.52)
83.96 
(45.76–159.46)
Total annual 
health care costs
247.28b 
(108.30–489.01)
261.60 
(116.69–510.31)
244.95 
(108.92–470.83)
418.39b 
(230.12–752.58)
396.54 
(220.61–687.39)
428.19 
(242.91–765.96)
Total annual 
health care costs excl 
iCs
247.28b 
(108.30–489.01)
261.60 
(116.69–510.31)
244.95 
(108.92–470.83)
390.93a 
(210.91–717.65)
366.05 
(198.58–649.00)
386.32 
(204.32–697.45)
Notes: Values shown are n (%) or median (interquartile range). Costs are per person in 2007 pounds sterling (£) for the baseline year. aP # 0.05, bP # 0.01 for comparison 
among the three cohorts. cAsthma control was defined as no recorded hospital attendance for asthma, oral corticosteroid prescription, or lower respiratory tract infection 
requiring antibiotics.
Abbreviations: Asthma/resp, asthma and respiratory; BAi, breath-actuated inhaler; DPi, dry powder inhaler; excl, excluding; iCs, inhaled corticosteroids; MDi, metered dose 
inhaler.
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used to represent comorbidities, as calculated for each patient 
using ICD-9 matching algorithms produced by CliniClue 
software (http://www.cliniclue.com/software).
For the cost analysis, unadjusted total health care costs 
per person in the baseline and outcome periods were sum-
marized using medians and compared across study groups 
using the Kruskal–Wallis test. Multivariate generalized linear 
models with a log link and gamma distribution were used to 
estimate total health care costs 1 year after the index date, 
controlling for age, sex, baseline asthma control status, and 
baseline total health care costs (logged). Adjusted costs were 
reported with 95% confidence intervals (CIs) for the differ-
ence in costs compared with MDI, which were obtained by 
the bootstrap method with 1000 replications.
The cost-effectiveness of the BAI and DPI inhalers were 
compared relative to the MDI in terms of cost per   additional 
patient achieving asthma control during the outcome 
year. The differences in costs and proportion of patients 
  achieving asthma control (after adjustment) for the 1,000 
replications were shown graphically on a cost-effectiveness 
plane. Incremental cost-effectiveness ratios (ICERs) were 
  calculated when the uncertainty in the data was restricted to 
one quadrant of the cost-effectiveness plane; ICERs cannot 
be calculated when the data cover more than one quadrant 
of the cost-effectiveness plane because of difficulties in 
interpreting and calculating CIs.38–40 The ICER is the ratio 
of the difference in costs to the difference in effectiveness 
of the two treatment arms, as depicted below:
 
ICER =
CC
EE
12
12
−
−
where C1 and E1 are the cost and effectiveness of the BAI 
or DPI, and C2 and E2 are the cost and effectiveness of the 
comparator (MDI).
Baseline statistical analyses were carried out using SPSS 
for Windows, (version 17.0; SPSS Inc. Chicago, IL). Boot-
strap analyses were carried out using STATA 9.2 for Windows 
(StataCorp LP, College Station, TX) and cost-effectiveness 
planes were derived using Microsoft Office Excel 2007 
(Microsoft Corp., Redmond, WA).
Results
Patients identified in the GPRD as eligible for the study 
numbered 56,347 in the initiation population starting ICS 
and 9,169 in the step-up population receiving a first increased 
dose of ICS. Demographic and baseline characteristics of the 
two populations are summarized in Table 2.
Patients initiating inhaled corticosteroids
Of the 56,347 patients in the initiation population, 39,746 
(71%) were prescribed an MDI, 9,809 (17%) a BAI, and 6,792 
(12%) a DPI. During the baseline year, healthcare costs were 
significantly different among cohorts for several categories, 
including total asthma/respiratory costs and total annual 
  healthcare costs (both highest in the BAI cohort; Table 2); these 
costs were included as covariates in the adjusted analyses.ClinicoEconomics and Outcomes Research 2010:2
Table 3 Unadjusted median health care costs (2007 pounds sterling) over 1 year after index prescription for patients receiving a first 
prescription of inhaled corticosteroid
Metered dose 
inhaler (n = 39,746)
Breath-actuated  
inhaler (n = 9809)
Dry powder  
inhaler (n = 6792)
Median IQR Median IQR Median IQR
inhaled corticosteroids 15.74a 7.60–34.42 20.98 10.49–41.96 37.00 18.74–74.00
Oral corticosteroids 0a 0–0 0 0–0 0 0–0
sABA inhalers 4.41a 1.47–8.82 6.30 2.32–13.95 8.39 2.94–20.76
Total asthma-related drugs 25.18a 13.27–49.91 34.41 17.84–67.16 55.50 28.53–108.87
Total asthma-related drugs excl iCs 4.83a 2.32–12.00 8.34 2.94–20.08 11.83 5.16–25.10
Total drug costs 54.66a 26.86–118.31 66.63 34.03–141.62 86.03 46.33–179.62
Total drug costs excl iCs 29.18a 11.34–80.85 35.38 14.10–96.00 33.91 14.25–87.43
Asthma consult, primary care 68.00a 34.00–102.00 68.00 34.00–102.00 68.00 34.00–102.00
Other gP consultation 204.00a 102.00–340.00 204.00 102.00–340.00 170.00 102.00–306.00
Total asthma-related costs 87.62a 48.87–154.63 107.53 57.84–181.31 128.76 74.33–221.98
Total asthma-related costs excl iCs 70.32a 36.32–114.96 75.40 40.02–141.41 76.84 40.92–142.92
Total annual health care costs 378.87a 212.04–676.00 412.47 228.75–720.23 400.84 226.75–699.24
Total annual health care costs excl iCs 353.04a 188.66–642.93 379.13 206.04–680.29 342.38 183.70–626.05
Notes: aP # 0.01 for comparisons among cohorts. Combination inhalers, long-acting β2 agonists, leukotriene receptor antagonists, theophylline, antibiotics, and all hospital 
visits were infrequently prescribed/recorded; thus median (iQR) costs were 0 (0–0) for these categories.
Abbreviations: excl, excluding; gP, general practice; iCs, inhaled corticosteroids; iQR, interquartile range; sABA, short-acting β2 agonist.
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During the outcome year, health care costs per person 
were significantly different among cohorts for most resource 
categories (Table 3). Total asthma-related drug costs were 
  significantly higher in the DPI cohort, with costs for ICS 
  double those for MDI and BAI cohorts. Total annual   health care 
costs, both including and excluding ICS, were highest in the 
BAI cohort. When ICS costs were excluded, the median total 
annual health care resource costs were £353, £379, and £342 
for MDI, BAI, and DPI cohorts, respectively (Table 3).
Adjusted mean total annual health care costs per person 
were significantly higher (P # 0.05) for patients prescribed 
a DPI by approximately £32, as compared with costs for 
those prescribed an MDI. Costs were on average £9 more for 
a BAI compared with an MDI, a nonsignificant   difference 
(Table 4).
The asthma control measure was achieved during the 
outcome year by 29,961 (75%), 7,518 (77%), and 5,307 
(78%) patients in MDI, BAI, and DPI cohorts, respectively 
(P # 0.001). The revised asthma control measure incorporat-
ing SABA use was achieved by 21,956 (55%), 5,605 (57%), 
and 4,185 (62%) of patients in MDI, BAI, and DPI cohorts, 
respectively (P # 0.001).
After adjustment for confounding factors, the propor-
tions of patients achieving asthma control relative to the MDI 
cohort were significantly greater (by 1%−2%; P # 0.05) 
for those patients who received a BAI or DPI (Table 4). 
There was a 94% probability of BAIs being more effective 
but also more costly than MDIs; a 5% probability of BAIs 
being the dominant strategy (more effective and less costly 
than MDIs); and a 1% probability that BAIs were less effec-
tive and more costly (Figure 1a). DPIs were consistently 
more effective and more costly than MDIs, representing a 
trade-off between more patients achieving asthma control 
but at greater cost than with an MDI. The ICER for DPIs 
was £1711 (95% CI: 760–3576) per additional patient with 
asthma control.
In terms of the revised asthma control measure that included 
SABA use, after adjustment the proportion of patients with 
asthma control remained significantly greater by 1% for the 
BAI and 5% for the DPI cohorts as compared with the MDI 
cohort (Table 4). As for the primary asthma control measure, 
there was a 94% probability of greater effectiveness but greater 
costs for BAIs compared with MDIs; a 5% probability of BAIs 
being the dominant strategy; and a 1% probability of BAIs 
being less effective and more costly (Figure 1b). DPIs remained 
consistently more effective but also more costly compared with 
MDIs; the ICER was £631 (95% CI: 349–983).
Patients receiving an increased  
dose of inhaled corticosteroids
Of the 9,169 patients in the step-up population, 6,245 (68%) 
were prescribed an MDI, 1,388 (15%) a BAI, and 1,536 (17%) 
a DPI. During the baseline year, health care costs were signifi-
cantly different across cohorts for several resource categories, 
including total asthma/respiratory costs and total annual health 
care costs (both highest in the DPI cohort; Table 2).
Asthma-related and total health care costs during the 
  outcome year are summarized in Table 5. Median costs ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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were significantly different among the three cohorts and 
were   highest in the DPI cohort for most health care resource 
  categories. Large cohort differences were evident in the costs 
of ICS and SABA inhalers, with costs for the DPI cohort 
being twice as high as those for the MDI cohort. When ICS 
costs were excluded, the median total annual health care 
resource costs were £429, £398, and £440 for MDI, BAI, 
and DPI cohorts, respectively (Table 5).
After adjusting for confounding factors, mean total 
annual health care costs per person were significantly 
higher (by £73; P # 0.05) for patients prescribed a DPI 
as compared with those prescribed an MDI (Table 4). 
The £1   difference between MDI and BAI cohorts was not 
  statistically significant.
During the outcome year, 4,237 (68%), 1,032 (74%), 
and 1,103 (72%) patients in the MDI, BAI, and DPI cohorts, 
Table 4 incremental cost and incremental effectiveness analyses for the 1 year after index prescription for patients receiving an 
increased dose or first prescription of inhaled corticosteroid: adjusted results
Patients starting ICS Patients receiving an increased dose of ICS
MDI 
(n = 39,746)
BAI 
(n = 9,809)
DPI 
(n = 6,792)
MDI 
(n = 6,245)
BAI 
(n = 1,388)
DPI 
(n = 1,536)
Adjusted total annual  
health care costs, 2007 £b:
Mean total costs 
(95% Ci)
541.13 
(535.93–546.18)
550.42 
(540.67–559.60)
573.03 
(560.89–584.56)
671.29 
(656.76–686.09)
672.34 
(645.20–700.75)
744.05 
(717.99–774.86)
Difference from MDi 
(95% Ci)
– 9.30 
(−1.65–19.71)
31.90a 
(19.51–43.66)
– 1.05 
(−27.28–31.55)
72.57a 
(44.48–103.29)
Effectiveness resultsc:
% Asthma controlledd 
(95% Ci)
75.49 
(75.04–75.92)
76.67 
(75.82–77.50)
77.53 
(76.56–78.48)
68.58 
(67.38–69.80)
72.24 
(69.94–74.54)
70.85 
(68.75–73.14)
Difference from MDi 
(95% Ci)
– 1.18a 
(0.25–2.11)
2.05a 
(0.97–3.11)
– 3.66a 
(1.15–6.19)
2.27 
(−0.26–4.90)
% Asthma controlled (revised)e 
(95% Ci)
55.48 
(55.03–55.95)
56.80 
(55.82–57.72)
60.64 
(59.56–61.85)
37.74 
(36.50–39.15)
38.89 
(36.54–41.39)
38.36 
(36.04–40.87)
Difference from MDi 
(95% Ci)
– 1.32a 
(0.28–2.34)
5.16a 
(3.95–6.32)
– 1.15 
(−1.27–3.81)
0.62 
(−2.06–3.21)
Notes:  aP # 0.05 for comparison with MDi cohort.  bTotal health care costs from 1,000 repetitions, adjusted for age, sex, baseline asthma control status, and baseline total health care 
costs including iCs. cAdjusted results based on 1000 repetitions. dAsthma control was defined as no recorded hospital attendance for asthma, oral corticosteroid prescription, or 
lower respiratory tract infection requiring antibiotics.  eRevised asthma control measure including average daily sABA use restricted to #200 µg salbutamol and #500 µg terbutaline. 
Abbreviations: BAI, breath-actuated inhaler; CI, confidence interval; DPI, dry powder inhaler; MDI, metered dose inhaler.
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Figure 1A Cost-effectiveness plane for patients receiving a first prescription of ICS. 
Note: Asthma control was defined as no recorded hospital attendance for asthma, oral corticosteroid prescription, or lower respiratory tract infection requiring antibiotics.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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respectively, achieved the asthma control measure, with the 
differences among cohorts being significant (P # 0.001). 
The revised asthma control measure incorporating SABA 
use was achieved by 2,289 (37%), 584 (42%), and 610 (40%) 
of patients in the MDI, BAI, and DPI cohorts, respectively 
(P # 0.001).
After adjustment for confounding factors, the proportion 
of patients achieving asthma control relative to the MDI 
cohort was significantly greater in the BAI cohort, by 3.7%. 
On average, an additional 2.3% of DPI patients achieved 
asthma control but this was not significantly different from 
the MDI cohort (Table 4). As shown in Figure 2a, there was 
a 48% probability of BAIs being the dominant strategy and 
a 52% probability that BAIs were more effective and more 
costly than MDIs. The probability that DPIs were more 
effective and more costly than MDIs was 96%, represent-
ing a trade-off between more patients achieving asthma 
control but at greater cost than with an MDI. There was a 
4% probability of DPIs being less effective and more costly 
than MDIs.
For the revised asthma control measure that included 
SABA use, there was no statistically significant difference in 
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Figure 1B Cost-effectiveness plane for patients receiving a first prescription of ICS (revised asthma control). 
Note: Asthma control (revised) was defined as asthma control plus average daily short-acting β2 agonist use restricted to #200 µg salbutamol and #500 µg terbutaline.
Table 5 Unadjusted median health care costs (2007 pounds sterling) over 1 year after index prescription for patients receiving an 
increased dose of inhaled corticosteroid, by inhaler device type
Metered dose inhaler  
(n = 6245)
Breath-actuated inhaler  
(n = 1388)
Dry powder inhaler  
(n = 1536)
Median IQR Median IQR Median IQR
inhaled corticosteroids 41.94b 20.97–79.23 42.99 20.98–81.92 85.04 40.86–166.50
Oral corticosteroids 0b 0–0 0 0–0 0 0–0
sABA inhalers 7.35b 2.94–16.27 12.42 5.88–25.20 13.98 6.92–34.60
Total asthma-related drugs 66.14b 32.32–149.53 73.44 38.34–147.16 131.79 65.69–265.78
Total asthma-related drugs excl iCs 13.30b 4.65–55.79 18.61 6.30–54.09 27.34 9.95–79.81
Total drug costs 114.37b 54.13–262.15 115.74 60.19–242.07 183.96 92.25–369.53
Total drug costs excl iCs 56.89b 20.48–179.74 58.35 23.47–157.47 66.35 25.66–195.03
Asthma consult, primary care 68.00 34.00–102.00 68.00 34.00–102.00 68.00 34.00–136.00
Other gP consultation 204.00a 102.00–374.00 204.00 102.00–374.00 204.00 102.00–340.00
Total asthma-related costs 146.53b 80.87–280.43 149.88 86.45–258.51 221.13 123.50–398.89
Total asthma-related costs excl iCs 88.88b 41.44–198.04 93.20 42.82–182.60 109.52 51.64–227.10
Total annual health care costs 484.68b 275.15–878.44 462.34 257.81–829.67 549.69 318.02–967.20
Total annual health care costs excl iCs 428.98 231.59–787.60 398.20 214.19–764.30 439.82 225.71–800.34
Notes: aP , 0.05. bP , 0.01 for comparison among cohorts. Combination inhalers, long-acting β2 agonists, leukotriene receptor antagonists, theophylline, antibiotics, and all 
hospital visits were infrequently prescribed/recorded; thus median (iQR) costs were 0 (0–0) for these categories.
Abbreviations: excl, excluding; gP, general practice; iCs, inhaled corticosteroids; iQR, interquartile range; sABA, short-acting β2 agonist.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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effectiveness between the BAI or DPI cohorts compared with 
the MDI cohort after adjustment for baseline   confounding 
variables. The probability of BAIs being the dominant 
  strategy was 41%; of BAIs being more effective and more 
costly than MDIs was 40%; of BAIs being less effective and 
less costly was 7%; and of BAIs being less effective and 
more costly was 12% (Figure 2b). For DPIs, the probability 
of being more effective but more costly was 67%, and of 
being less effective and more costly was 33%.
Discussion
The purpose of this study was to evaluate the cost-effectiveness 
of three different inhaler devices for delivering ICS to patients 
with asthma in a real world setting. The study results indicate 
that, during the first year after the initiation of ICS, both BAI 
and DPI devices were more effective than MDI devices, as 
significantly more patients achieved asthma control, by both 
study definitions, with a BAI or DPI than with an MDI. 
During the outcome year, DPIs, but not BAIs, were associ-
ated with significantly higher mean health care costs than 
MDIs. Overall, BAIs were more effective, by either asthma 
control definition, but had a 94% probability of also being 
more costly; DPIs were consistently more effective and more 
costly, with ICERs of £1711 (95% CI: 760–3576) and £631 
(95% CI: 349–983) per additional patient achieving asthma 
control, depending on definition.
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Figure 2A Cost-effectiveness plane for patients receiving an increased dose of iCs. 
Note: Asthma control was defined as no recorded hospital attendance for asthma, oral corticosteroid prescription, or lower respiratory tract infection requiring antibiotics.
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Figure 2B Cost-effectiveness plane for patients receiving an increased dose of iCs (revised asthma control). 
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For patients receiving an increased dose of ICS, those 
prescribed a BAI were, on average, significantly more likely 
to achieve asthma control than those prescribed an MDI, 
with similar total annual health care resource costs. Patients 
prescribed a DPI were as likely to achieve asthma control 
as those prescribed an MDI, but with significantly higher 
associated costs. Overall, in the cost-effectiveness analyses, 
BAIs were consistently more effective than MDIs and almost 
evenly split with regard to costs as compared with MDIs, 
namely, the dominant strategy (more effective, less costly) 
about half the time and more effective but more costly about 
half the time, whereas DPIs had a high probability (96%) 
of being more effective but more costly than MDIs. When 
the revised definition of asthma control was applied, the 
  probabilities of BAIs and DPIs being more effective but more 
costly were 47% and 67%, respectively; and the probability 
of BAIs being the dominant strategy was 41%.
The costs reported in this study are the direct medical 
costs from the perspective of the UK NHS (2007 pounds 
sterling) over 1 year after initiation or an increase in dose 
of ICS therapy. The total health care costs used to calculate 
the additional cost for one patient to achieve asthma control, 
adjusted for confounding factors, included the actual cost of 
the ICS devices, as well as all other health care expenditures 
captured from data recorded in the GPRD. Because there is 
no recognized threshold for the additional expenditure that is 
justified to provide one additional patient with asthma control, 
and because indirect costs were not measured, it is beyond the 
scope of this study to conclude whether the additional cost of 
a BAI or DPI is ‘worth it,’ as this will depend on the decision 
maker’s willingness to pay. However, for patients receiving 
an increased dose of ICS, one could argue that a BAI should 
be prescribed in preference over an MDI as BAIs were more 
effective than MDIs in this study. Moreover, BAIs appear to 
be the most cost-effective option as there was almost a 50% 
chance that a BAI would be less costly as well as more effec-
tive than an MDI for patients receiving an increased dose of 
ICS. In the remainder of cases there was a trade-off between 
greater costs and greater effectiveness.
For patients initiating ICS, the situation is less clear, 
although, on average, both BAIs and DPIs were more   effective 
than MDIs, and BAIs were not significantly more costly than 
MDIs. The chance of BAIs being dominant (both less costly 
and more effective than MDIs) was 5%, and when there was 
a trade-off between greater costs and greater   effectiveness, 
the trade-off was lower than for DPIs.
In general, the cost-effectiveness of ICS therapy for 
patients with persistent asthma is widely accepted. As much 
of the costs of asthma derive from poorly controlled disease, it 
would follow that improved control can lower asthma-related 
costs.5 Indeed, results of a health economic analysis alongside 
a long term randomized trial indicated that improvement in 
asthma control is associated with favorable cost per quality-
adjusted life-year.41 While most prior health economic studies 
of asthma therapy have compared controller medications,24,42 
cost-effectiveness comparisons of inhaler devices are few and 
different in scope to the present study.42–44 The findings of 
this study are supported, however, by assessments of inhaler 
technique, which indicate that patients tend to make fewer 
mistakes with BAIs and DPIs.15,16
For the initiation and step-up populations in this study, 
the ICS device prescribed was an MDI for 71% and 68%, 
respectively, a BAI for 17% and 15%, respectively, and a 
DPI for 12% and 17%, respectively, ratios approximating 
the wider market shares of these devices in the UK. Of the 
BAI devices for ICS prescribed in the UK over the course 
of the study, approximately 73% were Easi-Breathe® (Teva 
Pharmaceutical Industries Ltd., Petach Tikva, Israel) and 
27%, the Autohaler™ (Teva Pharmaceutical Industries Ltd., 
and 3M, St. Paul, MN, USA).45
Asthma control, simply defined, is the control of   clinical 
manifestations of asthma, including day and nighttime 
symptoms, limitations in the activities of daily living, and 
exacerbations. While parameters such as lung function 
are important measures of successful treatment, at the end 
of the day, asthma control is of practical importance to 
patients. The composite measure of asthma control used in 
this study was designed to capture outcomes recorded in the 
GPRD   indicating that an asthma exacerbation had occurred, 
  including: unplanned medical care or hospitalization for 
asthma, a prescription for oral corticosteroids, and antibiotic 
prescribing for lower respiratory tract infection, as acute 
asthma may be confused in practice for respiratory infection. 
These outcomes are in line with recent recommendations 
by the American Thoracic Society/European Respiratory 
Society task force for assessing asthma control in clinical 
trials,46 as well as those of the authors of a recent review of 
health economic studies in asthma.24
The limitations of this study are inherent to all   observational 
studies, including nonrandom allocation of treatments and the 
possibility of unrecognized confounding factors. While the 
GPRD is regarded as a high quality database,29,30 errors and 
omissions in medical record reporting are possible, and the 
database contains limited information on hospitalizations. 
Nonetheless, the large size of the GPRD, representing over 
5% of the UK population,27 makes it a valuable source for ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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study of primary care practice, where most asthma is   managed 
in the UK. Moreover, outcomes were studied over the course 
of 1 year, a period sufficient to capture seasonal variations in 
asthma and some of the fluctuations in   sym  ptoms   characteristic 
of this chronic respiratory condition.
Conclusion
In clinical practice, there can be considerable pressure to 
use the least expensive, most effective inhaled therapies and 
the most appropriate inhaler devices available to minimize 
the burden of asthma treatment costs for the UK NHS. Health 
economic assessments are important to aid decision mak-
ers in determining the optimal allocation of resources. The 
results of this retrospective observational study indicate that 
inhaler device selection does indeed matter for real world 
patients   prescribed ICS. Specifically, the results indicate that 
for patients initiating ICS, BAIs were more effective than MDIs 
most of the time, and, while the probability of BAIs being more 
costly than MDIs was 94%, mean health care costs with BAIs 
were not significantly greater than with MDIs. Instead, DPIs 
were consistently more effective and expensive than MDIs, 
with an incremental cost-effectiveness ratio of £631–1,711 per 
additional patient achieving asthma control, depending on con-
trol definition. For those patients receiving an increased dose 
of ICS, more patients can achieve asthma control with little 
or no additional cost relative to an MDI if prescribed a BAI. 
DPIs were usually more effective than MDIs but also more 
costly for this patient population. These findings suggest that 
the real world effectiveness of ICS inhalers may vary and that 
the selection of inhaler device for patients with asthma should 
take into consideration not only initial cost of the device itself 
but also the subsequent health care resource costs.
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